Key result
QNACR demonstrated cytotoxic and selective effects against MCF7 breast cancer cells (IC50 < 25 µM) by inducing reactive oxygen species and modifying oxidative status.
The novel compound QNACR exhibits cytotoxic and pro-oxidative effects in MCF7 breast cancer cells, highlighting its potential for antitumour therapy.
Answers are grounded in this paper and cite their sources.
Does not support clinical use in breast cancer; leaves open further preclinical validation of QNACR.
CONTEXT: Characterization of the pro-oxidant activity of QNACR. OBJECTIVES: Reactive oxygen species (ROS) induce cellular damage and represent unique opportunities to kill malignant cells. In this study, we synthesized and evaluated the new compound, (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl) acrylate (QNACR) as potential pro-oxidative agent against breast cancer. METHODS: Oxidative stress biomarkers such as ROS, thiobarbuturic acid reactive species (TBARs) and different antioxidant enzyme activities were determined in cell lysates. RESULTS: QNACR showed cytotoxic and more selective effects to tumour MCF7 cells (IC50 < 25 µM) compared to antitumour controls, inducing ROS and TBARs parallel to inhibitions of catalase (CAT), glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6PGDH). Longer exposures to QNACR triggered adaptive effects increasing the overall activities of CAT, glutathione reductase, G6PDH and 6PGDH, but eventually the adaptation changes faded and cells died. CONCLUSION: QNACR led to remarkable modifications in the oxidative status of tumour cells, proposing this compound as potential alternative for antitumour therapy.
No takes yet. Share an insight, caveat, or question.
Rodrígues et al. (2012) studied Breast cancer. (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl) acrylate (QNACR) vs. antitumour controls was evaluated on Cytotoxicity and oxidative stress biomarkers (ROS, TBARs, antioxidant enzyme activities). QNACR demonstrated cytotoxic and selective effects against MCF7 breast cancer cells (IC50 < 25 µM) by inducing reactive oxygen species and modifying oxidative status.
Synapse has enriched 10 related papers. Consider them for comparative context: